Physician profile
Marla Bishop
NPI 1588164693
$4,774.14
in general payments reported to CMS, 2019-2025
24 companies · $1,073 in 2025
The $1,073 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,114 · 2022: $614 · 2023: $920 · 2024: $1,053 · 2025: $1,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,046.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,636.55 | 2021-2025 | |
| Pfizer INC. | $558.25 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $389.53 | 2021-2024 | Xifaxan |
| Madrigal Pharmaceuticals | $313.67 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $302.09 | 2021-2025 | Stelara, Tremfya, Simponi |
| Aimmune Therapeutics, INC. | $209.04 | 2024-2025 | Vowst, Zenpep |
| Evoke Pharma, INC. | $208.17 | 2021-2025 | Gimoti |
| Regeneron Healthcare Solutions, INC. | $180.97 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $151.41 | 2024-2025 | Livdelzi |
| Intercept Pharmaceuticals, INC. | $149.57 | 2021-2025 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $109.46 | 2021-2024 | Entyvio, Gattex |
| Celgene Corporation | $105.75 | 2022-2023 | Zeposia |
| Genzyme Corporation | $105.29 | 2023-2025 | |
| Vivus LLC | $69.62 | 2021-2024 | Pancreaze |
| Mallinckrodt Hospital Products INC. | $47.09 | 2024 | Terlivaz |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $38.61 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $36.27 | 2024 | Bylvay, Iqirvo |
| Merck Sharp & Dohme LLC | $33.41 | 2022-2023 | Dificid |
| Lilly USA, LLC | $29.92 | 2024 | Mounjaro |
| Redhill Biopharma INC. | $25.07 | 2022-2023 | Talicia, Movantik, Aemcolo |
| Astrazeneca Pharmaceuticals LP | $22.22 | 2023 | Andexxa |
| E.R. Squibb & Sons, L.L.C. | $20.18 | 2022 | |
| Nestle Healthcare Nutrition INC. | $17.85 | 2021 | |
| Amgen INC. | $14.15 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marla Bishop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.